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ABSTRACT
Introduction The National Health Service for England 
Long Term Plan identifies respiratory disease as one of 
its priority workstreams. To assist with earlier and more 
accurate diagnosis of lung disease they recommend 
improvement in delivery of quality- assured spirometry. 
However, there is a likelihood that patients will present 
with abnormal gas exchange when spirometry results are 
normal and therefore there will be a proportion of patients 
whose time to diagnosis is still protracted. We wished to 
determine the incidence rate of this occurring within our 
Trust.
Methods A retrospective review of all patients attending 
the lung function laboratory for their first pulmonary 
function assessment from June 2006 to December 2020 
was undertaken. Forced expiratory volume in 1 s/forced 
vital capacity (FEV1/FVC) >−1.64 standardised residual 
(SR) was used to confirm no obstructive lung function 
abnormality and FVC >−1.64 SR to confirm no suggestion 
of a restrictive lung function abnormality. Lung gas transfer 
for carbon monoxide (TLCO) and transfer coefficient of the 
lung for carbon monoxide (KCO) <−1.64 SR confirmed the 
presence of a gas exchange abnormality. Spirometry and 
gas transfer reference values generated by the Global Lung 
Initiative were used to determine normality.
Results Of 12 835 eligible first visits with normal FEV1/
FVC and FVC, 4856 (37.8%) were identified as having an 
abnormally low TLCO and 3302 (25.7%) presenting with an 
abnormally low KCO. Of 3494 with FEV1/FVC SR <−1.64, 
3316 also had a ratio of <0.70, meaning 178 (5%) of 
patients in this cohort would have been misclassified 
as having obstructive lung disease using the 0.70 cut- 
off recommended by the Global Initiative for Chronic 
Obstructive Lung Disease for diagnosing obstructive lung 
disease.
Discussion In conclusion, to assist with ensuring more 
accurate and timely diagnosis of lung disease and 
enhance patients’ diagnostic pathway, we recommend the 
performance of lung gas transfer measurements alongside 
spirometry in all healthcare settings. To assess and monitor 
gas transfer at the earliest opportunity we recommend this 
is implemented into new models being developed within 
community hubs. This will increase the identification of 
lung function abnormalities and provide patients with a 
definitive diagnosis earlier.
BACKGROUND
Respiratory disease is the third biggest cause 
of death in the UK and affects one in five 
people in England, with no improvement in 
respiratory disease mortality rates for over 
10 years.1 In light of this and for the first 
time, the National Health Service in England 
(NHSE) has designated respiratory disease 
as a clinical priority as part of its Long Term 
Plan. The plan highlights the importance of 
reaching an earlier and more accurate diag-
nosis as an objective.2 To address the short-
falls surrounding time and accuracy of diag-
nosis, the NHSE Long Term Plan advocates 
the performance of quality- assured spirom-
etry in the community.
Spirometry is the most common pulmonary 
function test undertaken and is used world-
wide as the first- line diagnostic tool in the 
primary care setting when attempting to iden-
tify lung disease.3 4 It is an effective procedure 
for differentiating obstructive from other 
lung function abnormalities.5 The use of 
quality- assured spirometry is recommended 
frequently in national and international 
guidelines for the diagnosis and manage-
ment of asthma and chronic obstructive 
pulmonary disease (COPD) both in primary 
and secondary care.6–8 However, the ability 
of the respiratory system to exchange gases 
to and from the cardiovascular system can 
be impaired despite the presence of normal 
spirometry.9 Anecdotally, we were aware of 
patients presenting with normal spirometry 
results and yet abnormal gas exchange as 
measured by the single breath technique. 
We believe it is important to understand the 
impact measuring gas transfer might have 
on our ability to diagnose lung disease that 
spirometry alone might miss. This would 
clearly have the potential to influence future 
Key messages
 ► Spirometry alone does not help to identify all respi-
ratory diagnoses earlier.
 ► Enhanced lung function testing will assist in iden-
tifying patients with respiratory abnormalities that 
spirometry alone misses.
 ► We demonstrate why enhanced lung function testing 
is important and the proportion of patients this will 
benefit.
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strategy on the ability to identify lung disease earlier. Due 
to alterations in the alveolar- capillary membrane and 
lung vasculature, the lung diseases that this would impact 
would include pulmonary vascular disorders, early inter-
stitial lung disease or early emphysema.9
Our aim was to investigate what proportion of patients 
attending our department for their first diagnostic assess-
ment presented with normal spirometry yet abnormal gas 
transfer. This will impact time to first diagnoses, resulting 
in a continued protracted pathway and reducing the 
ability to detect lung disease at the earliest opportunity.
METHODS
A retrospective review of all patients referred to 
Cambridge University Hospitals’ lung function depart-
ment for their first diagnostic assessment from June 
2006 to December 2020 was undertaken. Spirometry and 
single breath gas transfer were performed to European 
Respiratory Society (ERS)/American Thoracic Society 
(ATS) standards.10 11 Global Lung Initiative (GLI)12 
reference equations were used to determine normality. 
Forced expiratory volume in 1 s/forced vital capacity 
(FEV1/FVC) >−1.64 standardised residual (SR) was used 
to confirm no obstructive lung function abnormality and 
FVC >−1.64 SR to confirm no suggestion of a restrictive 
lung function abnormality. Lung gas transfer for carbon 
monoxide (TLCO) and transfer coefficient of the lung 
for carbon monoxide (KCO) <−1.64 SR confirmed the 
presence of a gas exchange abnormality.
Due to the limits of the GLI reference data set, gas 
transfer data had to be excluded for all non- Caucasian 
patients and those older than 85 years of age.
Patient and public involvement
This analysis was based on anonymised retrospective data 
from historical lung function results.
RESULTS
Of 27 856 first visits, data from 1224 non- Caucasian 
patients and 638 patients older than 85 years of age had 
to be excluded (figure 1).
Of 25 994 subsequent first visits, 8816 had missing 
single breath gas transfer data. Of these 3494 were 
identified as having an abnormal FEV1/FVC and 849 as 
having an abnormal FVC. Of the 3494 with FEV1/FVC 
SR <−1.64, 3316 also had a ratio of <0.70, meaning 178 
(5%) of patients in this cohort would have been misclassi-
fied as having obstructive lung disease using the 0.70 cut- 
off recommended by the Global Initiative for Chronic 
Obstructive Lung Disease for diagnosing obstructive lung 
disease.
Of the remaining 12 835 results, 4856 (37.8%) 
presented with an abnormally low TLCO and 3302 
(25.7%) presenting with an abnormally low KCO. Infor-
mation on this group is found in table 1.
Of 4856 with an abnormal TLCO, 3040 also had an 
abnormal KCO. Of 4856 patients 2029 had an abnormal 
Alveolar Volume (VA). Of the patients 937 had an 
abnormal TLCO, KCO and VA combined. Of the 262 
with an isolated low KCO, 45 also had an elevated VA and 
the remainder all had normal VA. Information on this 
group is found in table 2
DISCUSSION
We have demonstrated that a proportion of patients 
referred to secondary care for their first respiratory 
diagnostic assessment present with normal spirometry 
yet abnormal gas transfer. These results have implica-
tions when solely using spirometry in order to detect 
respiratory function abnormalities earlier and could 
ultimately result in a continued protraction of patient 
diagnosis. These results support the proposed diagnostic 
pathway for patients presenting with breathlessness to 
Figure 1 A flow diagram demonstrating the number of 
patients included in each step of the analysis. FEV1, forced 
expiratory volume in 1 s; FVC, forced vital capacity.




Age (years) 61.0 16.1
FEV1 SR 0.92 1.24
FVC SR 1.40 1.40
FEV1/FVC SR 0.11 0.76
TLCOc SR −1.35 1.73
KCOc SR −0.79 1.51
Lung function results are presented as standardised residual (SR).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 
KCOc, transfer coefficient of the lung for carbon monoxide 
corrected; TLCOc, transfer for carbon monoxide corrected.
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a community practitioner suggested by the Taskforce 
for Lung Health, with the latest pathway including the 
performance of single breath gas transfer earlier within 
the patient’s diagnostic journey.
Within the NHSE Long Term Plan2 and the subsequent 
Richard’s review,13 there is emphasis on the National 
Health Service to do more to detect and diagnose respi-
ratory problems earlier and within a community setting. 
Performance of spirometry and improving the quality of 
assessment are highlighted as methods to achieve this 
aim within the NHSE Long Term Plan, particularly with 
regard to diagnosing COPD. Spirometry is clearly a key 
assessment to assist in providing a differential diagnosis 
of respiratory disease and is thought to be a relatively 
simple test to undertake. Recent equipment innovation 
means that ambulatory equipment is now available for 
the performance of gas transfer as well as spirometry. 
In addition, the performance of gas transfer is no less 
arduous than that of spirometry. However, consideration 
would need to be given to appropriate training and 
competency of healthcare professionals performing gas 
transfer. Training and certification on the performance 
of quality- assured spirometry are well established and 
provided by the Association for Respiratory Technology 
and Physiology. Consideration would need to be given 
regarding the training of healthcare professionals in 
addition to spirometry or whether addition of this test 
warrants greater input from those already trained in its 
performance, for example, physiologists. Currently the 
healthcare professionals that are appropriately trained 
in the performance of this measurement are healthcare 
scientists. Their advanced skills in the performance of 
gas transfer and other more advanced respiratory physio-
logical assessments would greatly assist in the earlier and 
more accurate diagnosis of lung disease in a community 
setting, for example, in community diagnostic hubs that 
are currently being established nationwide.
The importance of measuring diffusive capacity is also 
evident in the identification, monitoring and recovery 
of patients during the post- COVID-19 phase. Evidence 
in discharged COVID-19 survivors suggests impairment 
of diffusion capacity is the most common abnormality 
of lung function and is associated with severity of the 
disease, whereas even in the most severe cases spirom-
etry values largely remained within a normal range.14 15 
Furthermore, 52.6% of patients who performed pulmo-
nary function testing 30 days post- COVID-19 recovery 
presented with abnormal diffusion capacity.16 The 
British Thoracic Society guidance regarding respira-
tory follow- up in patients with COVID-19 highlights the 
importance of performing lung function testing and 
suggests the performance of full lung function tests 12 
weeks after discharge in those who were cared for in 
high- dependency or intensive care units.17
Of course our results also mean that there were a signifi-
cant proportion of patients in whom both spirometry and 
gas transfer were normal. In our current pathway patients 
are referred to the hospital with or without commu-
nity spirometry having been performed. On occasions 
when spirometry has been performed it is not always to 
a quality- assured standard and means a doubling- up on 
diagnostic procedures. The patient is then placed on an 
18- week referral to treat pathway. They will wait to see a 
clinician, wait again for diagnostic procedures and then 
wait again to return to see the clinician. Therefore our 
results demonstrate that there is an extra unnecessary 
burden on the healthcare system when diagnostic results 
come back normal. With the availability of these results 
much earlier in the patient pathway, the likelihood is 
that these patients would not have subsequently required 
a referral to secondary care for review and could have 
been managed within primary care. This then has impli-
cations in terms of the number of referrals required to 
secondary and tertiary care, which would likely decline. 
This reduces waiting times into secondary care, allowing 
patients with more complex disease to be seen earlier. 
There will also be savings within the overall healthcare 
economy and patient benefits through the following:
1. Ensuring patients receive a diagnosis early without the 
need to continue to return with ongoing symptoms 
suggestive of respiratory disease and the potential for 
unnecessary trials of medication prescriptions to try 
and alleviate ongoing symptoms, which will reduce 
costs of medications.
2. A reduction in unnecessary referrals: every referral 
from the community to secondary or tertiary care 
attracts a fee, such as Treatment Function Code 340 
Respiratory Medicine, which for a first attendance is 
£221. By undertaking appropriate diagnostics tests 
earlier in the pathway we could identify those patients 
who do not need to be referred further and thus sav-
ing this cost per patient as a minimum.
3. A reduction in non- essential diagnostic procedures: 
this ties in with point 1 above, but referral to second-
ary/tertiary care may also attract further unnecessary 
diagnostic assessments such as CT, which does not 
only result in a cost but also exposure to unnecessary 
radiation.
Table 2 Demographic information of first visit patients with 
normal spirometry but abnormal gas transfer
Male:female 2809:2047
Mean SD
Age (years) 67.1 13.2
FEV1 SR 1.18 1.23
FVC SR 1.72 1.40
FEV1/FVC SR 0.32 0.64
TLCOc SR −3.12 1.24
KCOc SR −2.14 1.28
Lung function results are presented as standardised residual (SR).
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; 
KCOc, transfer coefficient of the lung for carbon monoxide 
corrected; TLCOc, transfer for carbon monoxide corrected.
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4. A reduction in the number of consultations to the 
primary care practice with ongoing symptoms, freeing 
up time and space for the practice to handle calls and 
requests from more patients.
We have demonstrated that 5% of patients within 
our cohort would have been misclassified as having an 
obstructive pattern to their lung function by using a 
fixed ratio of 0.7 compared with the use of lower limits 
of normal (LLN) or SRs. The merits of using LLN and 
SRs have been well described elsewhere,18 and we would 
encourage readers to familiarise themselves with the 
utility of these parameters in comparison with fixed 
cut- offs.
There is a potential for bias in our sample. This retro-
spectively sampled cohort of patients were those who were 
referred to the Trust and then subsequently requested 
lung function assessments. It is likely that there were a 
proportion of patients seen within the thoracic medicine 
clinic that were managed by the clinical team without 
the need for lung function. This is only a snapshot in 
time. None of the patients was preselected for analysis; 
these were all comers that met the inclusion criteria and 
it appropriately reflects our practice. Another limitation 
to this study is that we do not know what happened to 
the patients in primary care for the equivalent period in 
terms of their diagnostic assessment and management. 
We also did not directly assess whether a normal spirom-
etry result in the community prevented a referral to 
secondary care. Clearly there are implications to patient 
diagnosis, management and ongoing care should a 
normal spirometry result in a patient with abnormal gas 
transfer not result in a secondary care referral. Specialist 
input into community diagnosis from trained healthcare 
professionals in respiratory diagnostic assessments would 
help to triage patients to the most appropriate pathway.
In conclusion, we recommend the performance of 
lung gas transfer alongside spirometry at the earliest 
opportunity within a patient’s diagnostic pathway. This 
will ensure more accurate and timely diagnosis of lung 
abnormalities associated with respiratory disease, with 
earlier detection of significant disease being enhanced by 
this approach. To assess and monitor gas transfer at the 
earliest opportunity we recommend this is implemented 
into new models being developed within community 
hubs. This will likely increase the identification of lung 
function abnormalities and provide patients with a defin-
itive diagnosis earlier.
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